Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of DA-5218 vs Co-administered Components in Healthy Volunteers
NCT05449704Phase 1Unknown
- Sponsor
- Dong-A ST
- Start
- Jul 2022
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of DA-5218 in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Dong-A ST. Primary endpoints: Area Under the Concentration-time Curve from time zero to the last measurable concentration and Maximum Plasma Concentration. Status: unknown.
02
Drugs
DA-5218
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05449704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05449704.